Myriad
Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.
UBS Initiates Coverage of Myriad Genetics With Neutral Rating
Analysts noted that while continued double-digit growth appears unsustainable in the near term, risks related to UnitedHealthcare's decision on pharmacogenetic testing appear limited.
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
In Brief This Week: Myriad Genetics, Thermo Fisher Scientific, DeepUll, Roche, Immunovia, More
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Mixed Month for Diagnostics Stocks as 360Dx Top 30 Ticks up 1 Percent in November
Out of the 30 companies tracked by 360Dx, 13 saw their share prices increase, while 17 saw their stock prices decline.
Nov 1, 2024
360Dx Top 30 Falls 3 Percent in October
Jul 1, 2024
360Dx Top 30 Slides 2 Percent in June
May 7, 2024